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Proton pump inhibitors (PPIs) have been used worldwide to treat gastrointestinal 28 
disorders. A recent study showed that long-term use of PPIs caused iron deficiency; 29 
however, it is unclear whether PPIs affect iron metabolism directly. We investigated 30 
the effect of PPIs on the peptide hepcidin, an important iron regulatory hormone. First, 31 
we used the FDA Adverse Event Reporting System database and analyzed the 32 
influence of PPIs. We found that PPIs, as well as H2 blockers, increased the odds ratio 33 
of iron-deficient anemia. Next, HepG2 cells were used to examine the action of PPIs 34 
and H2 blockers on hepcidin. PPIs augmented hepcidin expression, while H2 blockers 35 
did not. In fact, the PPI omeprazole increased hepcidin secretion, and 36 
omeprazole-induced hepcidin upregulation was inhibited by gene silencing or the 37 
pharmacological inhibition of the aryl hydrocarbon receptor. In mouse experiments, 38 
omeprazole also increased hepatic hepcidin mRNA expression and blood hepcidin 39 
levels. In mice treated with omeprazole, protein levels of duodenal and splenic 40 
ferroportin decreased. Taken together, PPIs directly affect iron metabolism by 41 
suppressing iron absorption through the inhibition of duodenal ferroportin via hepcidin 42 
upregulation. These findings provide a new insight into the molecular mechanism of 43 
PPI-induced iron deficiency. 44 
 45 




































































Abbreviations: AhR, aryl hydrocarbon receptor; DMT1, divalent metal transporter 1; 47 
FAERS, FDA Adverse Event Reporting System; FPN, ferroportin; FTH, ferritin heavy 48 
chain; FTL, ferritin light chain; OME, omeprazole; PPIs, protein pump inhibitors; 49 




































































1. Introduction 51 
Iron is an essential trace metal element in the body, and its deficiency causes 52 
anemia of microcytic and hypochromic corpuscles by interfering with hemoglobin 53 
synthesis. Almost all iron is recycled by the degradation of hemoglobin derived from 54 
old erythrocytes, however, it is also supplied by food. Iron has two forms, heme and 55 
non-heme. Whether non-heme iron is absorbed by the duodenum or the jejunum 56 
depends on a number of factors, including the presence of gastric acid (Zhang and Enns, 57 
2009). The acidic environment of the stomach promotes iron absorption by reducing 58 
insoluble iron (Fe3+) to soluble iron (Fe2+) ions and permitting the formation of soluble 59 
chelates (Jacobs and Miles, 1969). 60 
Worldwide, proton pump inhibitors (PPIs) and H2 blockers have been used 61 
for decades to treat gastric acid-related disorders (Scarpignato et al., 2006). Long-term 62 
use of PPIs or H2 blockers increases pH levels in the stomach by reducing the secretion 63 
of gastric acid, which decreases the digestion of proteins and the absorption of vitamins 64 
and minerals, including iron (Ito and Jensen, 2010). Several clinical studies have 65 
demonstrated that iron deficiency is induced in patients with long term use of PPIs and 66 
H2 blockers (Aymard et al., 1988; Lam et al., 2017). PPI- and H2 blocker-induced iron 67 
deficiency reduces iron absorption by altering the acidic environment of the 68 
gastrointestinal tract. 69 
Iron is normally absorbed from the small intestine via the action of 70 




































































and mitochondria of erythroblast, where it is used for heme synthesis, including the 72 
synthesis of hemoglobin. Hemoglobin is synthesized through an eight-step enzymatic 73 
cascade, and ferrous iron (Fe2+) is inserted into protoporphyrin IX to form a heme 74 
group at the last step (Severance and Hamza, 2009). Hepcidin, plays a crucial role in 75 
the regulation of systemic iron metabolism (Park et al., 2001), regulates the efflux of 76 
intracellular iron by inducing the internalization and degradation of FPN (Nemeth et al., 77 
2004). Therefore, iron absorption by the small intestine decreases as hepcidin levels 78 
increase. In fact, transgenic mice with hepatic hepcidin overexpression have severe 79 
iron deficiency anemia due to FPN downregulation, which reduces iron absorption 80 
(Nicolas et al., 2002). In humans, hepcidin is the key mediator of inflammation 81 
associated anemia. (Ganz, 2003).  82 
Here, we evaluated the effect of PPIs on iron absorption via hepcidin 83 
regulation. 84 
 85 
2. Materials and Methods 86 
2.1. Large-scale database analysis 87 
We used the World Medical & Drug Information Service to define drug 88 
names and the Medical Dictionary for Regulatory Activities (MedDRA/J) version 18D 89 
to define “iron deficiency anaemia”. We analyzed data recorded from January 2007 to 90 




































































Reporting System (FAERS) database, using reporting odds ratio (ROR), a signal 92 
detection method. The reports were divided into the following four groups: (a) 93 
individuals who received PPIs and exhibited iron deficiency anemia, (b) individuals 94 
who received PPIs but did not exhibit iron deficiency anemia, (c) individuals who did 95 
not receive PPIs and exhibited iron deficiency anemia, and (d) individuals who did not 96 
receive PPIs and did not exhibit iron deficiency anemia. ROR was calculated for each 97 
group using the following equation: ROR = (a/b)/(c/d), 95% CI= exp [log (ROR) ± 98 
1.96 √(1/a+1/b+1/c+1/d)]. We assumed that there was a signal when the calculated 99 
lower limit value of the 95% confidence interval of ROR was > 1 (van Puijenbroek et 100 
al., 2002). 101 
 102 
2.2 Chemicals and reagents 103 
Omeprazole (OME) was purchased from the Fujifilm Wako Pure Chemical 104 
Corporation, (Osaka, Japan); lansoprazole, rabeprazole, pantoprazole, and famotidine 105 
were purchased from the Tokyo Chemical Industry (Tokyo, Japan); and CH-223191, 106 
an aryl hydrocarbon receptor (AhR) inhibitor, was obtained from Sigma-Aldrich (St. 107 
Louis, MO, USA). The following commercially available antibodies were used in this 108 
study: anti-NRAMP2/divalent metal transporter 1 (DMT1), anti-ferritin heavy chain 109 
(FTH), anti-ferritin light chain (FTL), and anti-AhR antibodies were purchased from 110 
Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-transferrin receptor 1 (TfR1) 111 




































































Diagnostics; San Antonio, TX, USA); anti-α-tubulin (Merck KGaA, Darmstadt, 113 
Germany) was used as protein loading control; and anti-histone H3 antibody (Abcam, 114 
Cambridge, UK) was used as a loading control for nuclear proteins.  115 
 116 
2.3. Cell culture 117 
HepG2, a human hepatoma cell line, was purchased from the Japanese 118 
Collection of Research Bioresources (Osaka, Japan). The methods of cell culture have 119 
been described previously (Hamano et al., 2017). In brief, when the cells reached 120 
sub-confluency, the cells were placed in serum-free media overnight. Subsequently, the 121 
cells were treated with PPIs and an H2 blocker for 24 hours. In another experiment, 122 
cells were pre-treated for 1 hour with CH-223191 (AhR inhibitor) before stimulation 123 
with OME. 124 
 125 
2.4. Small interfering RNA experiments 126 
Small interfering RNA (siRNA) targeting human AhR, and a non-targeting 127 
siRNA control sequence, were obtained from Sigma Aldrich (Mission siRNA; Tokyo, 128 
Japan), and used as previously described (Hamano et al., 2017).  129 
 130 




































































All experimental animal procedures were performed in accordance with the 132 
guidelines of the Animal Research Committee of Tokushima University Graduate 133 
School (Permit Number: T30-125). Eight-week-old male C57BL6/J mice were 134 
purchased from Nippon CLEA (Tokyo, Japan). The mice were maintained under 135 
conventional conditions, with a regular 12-hour light/dark cycle. They were given free 136 
access to food (Type NMF; Oriental Yeast, Tokyo, Japan) and water during the study. 137 
OME (20 mg/kg/day) was orally administered to mice (Hess et al., 2015; Wang et al., 138 
2015) for 1 or 2 weeks. OME was suspended in 0.5 % carboxymethylcellulose. Control 139 
mice received orally-administered carboxymethylcellulose alone. The mice were 140 
euthanized by intraperitoneal over-dose injection of anesthetic. Tissues and blood 141 
samples were collected and stored at -80 °C until use. 142 
 143 
2.6. Measurement of plasma iron levels, plasma ferritin levels, tissue iron 144 
concentration, and peripheral blood  145 
Serum iron levels and tissue iron concentrations were measured using an iron 146 
assay kit (Metallo Assay) according to the manufacturer’s instructions (Metallogenics 147 
Co. Ltd., Chiba, Japan), and plasma ferritin levels were determined using a Mouse 148 
Ferritin ELISA Kit (Immunology Consultants Laboratory; Newberg, OR, USA) 149 
according to the manufacturer’s instructions (Hamano et al., 2017). Complete blood 150 





































































2.7. RNA extraction and evaluation of mRNA expression levels 153 
The methods of RNA extraction, cDNA synthesis, and quantitative RT-PCR 154 
have been described previously (Ikeda et al., 2016). The primer sets used were as 155 
follows: 5′-CTGCCTGTCTCCTGCTTCTC-3′ and 5′- 156 
AGATGCAGATGGGGAAGTTG-3′ for mouse hepcidin-1, and 157 
5′-GCTCCAAGCAGATGCAGCA-3′ and 5′-CCGGATGTGAGGCAGCAG-3′ for 158 
36B4 (an internal control). The expression levels of all target genes were normalized to 159 
36B4. Values were compared to the control group, and expressed as relative fold 160 
changes. 161 
 162 
2.8. Protein extraction and western blot analysis 163 
The methods of protein preparation and western blotting have been 164 
previously described (Ikeda et al., 2016). In brief, prepared protein samples were 165 
separated using SDS-PAGE and transferred onto a PVDF membrane. A 166 
chemiluminescent reagent was used to detect immunoreactive bands. Immunoblot 167 
bands were visualized by exposure to X-ray film or by a C-DiGit chemiluminescent 168 
scanner (LI-COR C-DiGit Blot Scanner, Lincoln, Nebraska, USA). Densitometry of 169 
the visualized bands was quantified using Image J 1.38x software (U. S. National 170 
Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2014). 171 
 172 




































































Hepcidin concentrations in mouse plasma and in cell culture media were 174 
measured using surface-enhanced laser desorption ionization time of flight mass 175 
spectrometry as described previously (Tomosugi et al., 2006). The assays were 176 
performed by the Medical Care Proteomics Biotechnology Co. Ltd. (Kanazawa, 177 
Japan).  178 
 179 
2.10. Statistical analysis 180 
Data are presented as the mean ± standard deviation (SD). An unpaired, 181 
2-tailed, Student’s t-test was used to compare two groups. To compare among more 182 
than two groups, the statistical significance of each difference was evaluated using a 183 
post-hoc test (either Dunnett’s method or Tukey-Kramer’s method). P values < 0.05 184 
indicated statistical significance. 185 
 186 
3. Results 187 
3.1. Analysis of the effects of PPIs and H2 blocker on iron deficiency anemia using the 188 
FAERS database 189 
A larger analysis to evaluate the influence of PPIs in iron deficiency anemia 190 
using data from many hospitals was conducted using the FAERS database (Table 1). 191 




































































anemia. Increasing RORs were observed in combination therapy that included OME 193 
(ROR = 3.90, 95% CI = 3.43–4.43), lansoprazole (ROR = 5.02, 95% CI = 4.27–5.89), 194 
rabeprazole (ROR = 7.29, 95% CI = 5.77–9.21), and pantoprazole (ROR = 4.75, 95% 195 
CI = 4.15–5.45). Similarly, the increase was observed for famotidine (ROR = 5.06, 196 
95% CI = 4.01–6.38). Consistent with a previous report (Lam et al., 2017), PPIs, as 197 
well as the H2 blocker, were significantly associated with the incidence of iron 198 
deficiency anemia by database analysis. 199 
 200 
3.2. Effect of PPIs and H2 blocker on hepcidin mRNA and secretion in HepG2 cells 201 
 We checked the action of PPIs and the H2 blocker on hepcidin expression in 202 
HepG2 cells. All PPIs, including OME, lansoprazole, rabeprazole, and pantoprazole 203 
enhanced hepcidin mRNA expression, but the H2 blocker, famotidine, did not (Fig. 204 
1A). In addition, secreted hepcidin-25 protein levels also increased in the culture 205 
medium with OME treatment (Fig. 1B).  206 
 207 
3.3. Effect of OME on hepcidin expression via an AhR-mediated pathway  208 
We previously reported that uremic toxin indoxyl sulfate-induced hepcidin 209 
upregulation is mediated through activation of the AhR (Diaz et al., 1990), and OME 210 




































































Consistent with these data, we found that OME promoted translocation of AhR from 212 
the cytosol to the nucleus in HepG2 cells (Fig. 1C). To examine whether OME-induced 213 
hepcidin upregulation was mediated through AhR, we used AhR-specific siRNA and 214 
the AhR inhibitor CH-223191. Both AhR silencing and CH-223191 reduced 215 
OME-induced hepcidin expression (Fig. 1D and E). These findings suggest that OME 216 
induces hepcidin upregulation via an AhR-mediated pathway. 217 
 218 
3.4. Changes of hepatic hepcidin mRNA and plasma hepcidin levels in OME-treated 219 
mice 220 
 To assess the effect of OME on iron metabolism in vivo, we administered 221 
OME orally to mice. Similar to the findings in HepG2 cells, hepatic hepcidin 222 
expression significantly increased in mice after both 1 and 2 weeks of OME treatment 223 
(Fig. 2A). Additionally, plasma hepcidin concentration increased after 1 week of OME 224 
treatment (Fig. 2B). 225 
 226 
3.5. Changes in ferroportin expression in OME-treated mice  227 
As expected, FPN expression decreased in the duodenum and the spleen of 228 
mice treated with OME (Fig. 2C and D); however, 1 week of OME treatment did not 229 




































































findings suggest that in mice treated with OME, reduced FPN expression is due to 231 
increased hepcidin production. 232 
 233 
3.6. Alteration of tissue and plasma iron content by OME administration  234 
We examined the iron content of the liver and iron concentration in the 235 
plasma of mice treated with OME. As shown in Table 2, OME administration for 1 or 236 
2 weeks did not change the iron content of the liver. Meanwhile, the incidence of 237 
anemia increased with reduced plasma iron levels. There were no differences in the 238 
protein expression of liver and spleen ferritin (Fig. 4), or in plasma ferritin levels at 2 239 
weeks when comparing vehicle-treated and OME-treated mice (OME 399.9 ± 48.1 240 




































































4. Discussion  242 
Using the FAERS database, we demonstrated that there is an increased risk 243 
of iron deficiency anemia in patients treated with PPIs or an H2 blocker. In vitro, we 244 
found that PPIs, but not the H2 blocker, upregulated hepcidin through the AhR 245 
pathway. Mice treated with OME had increased expression of hepatic hepcidin mRNA 246 
and higher plasma hepcidin levels, leading to a decrease in FPN expression in the 247 
duodenum and spleen. These findings indicate that PPI-induced iron deficiency 248 
involves a hepcidin-FPN dependent pathway in addition to elevated gastric pH levels. 249 
The FAERS is a database of self-reported drug-related adverse events from 250 
multiple treatment centers that reflects the realities of clinical practice. Patients treated 251 
with PPIs or an H2 blocker had a significantly higher rate of iron deficiency anemia 252 
compared to patients who had not taken PPIs or an H2 blocker. These data are 253 
consistent with (Lam et al., 2017) who found that patients who had taken PPIs 254 
long-term (i.e. for more than two years) were at increased risk of iron deficiency. This 255 
case-control study also showed that the risk of iron deficiency was higher in the 256 
patients using PPIs (adjusted odds ratio, 2.49) than in patients using H2 blockers (odds 257 
ratio, 1.58) (Lam et al., 2017). The subsequent risk for iron deficiency due to PPI use 258 
may be attributed to elevation of pH levels in the stomach and other factors. 259 
Hepcidin is an important iron regulator that controls cellular iron efflux via 260 




































































PPI treatment; however, famotidine, a H2 blocker, did not augment hepcidin 262 
expression in HepG2 cells. Hepcidin expression is regulated by many factors including 263 
iron, anemia, and inflammation (Ganz, 2011). In addition, indoxyl sulfate regulates 264 
hepcidin expression through an AhR-mediated pathway (Hamano et al., 2017), 265 
suggesting the involvement of AhR in hepcidin regulation. Previous studies have 266 
shown that OME activates AhR in hepatocytes (Diaz et al., 1990; Kashfi et al., 1995). 267 
Consistent with these data, we confirmed that OME promoted AhR translocation from 268 
the cytosol to the nucleus, suggesting that OME may be an activating ligand for AhR. 269 
Silencing or inhibiting AhR suppressed OME-induced hepcidin upregulation. Taken 270 
together, these data indicate that OME upregulates hepcidin through an AhR-mediated 271 
pathway.  272 
Similar to the effect of PPIs on hepcidin in vitro, mice treated with OME for 273 
1 week showed increased hepatic hepcidin mRNA expression and increased plasma 274 
hepcidin levels. The mice also displayed reduced FPN expression in the duodenum and 275 
spleen. Moreover, the increase in hepatic hepcidin mRNA lasted for 2 weeks, and the 276 
mice developed anemia, suggesting that iron absorption and utilization were impaired. 277 
Therefore, in addition to increasing gastrointestinal pH levels, PPIs may also inhibit 278 
iron absorption but regulating the hepcidin-FPN pathway. We did not find a decrease 279 
in hepatic iron content or ferritin expression, therefore, we propose that OME-induced 280 




































































necessary to further clarify the effect of PPIs on hepcidin, and on the induction of iron 282 
deficiency anemia. 283 
In conclusion, PPIs upregulate hepcidin expression by activating AhR. 284 
Increased hepcidin production by PPIs leads to a reduction in FPN expression, which 285 
inhibits iron absorption and utilization, and promotes the development of iron 286 
deficiency anemia. The effect of PPIs on iron metabolism suggests that the risk of iron 287 
deficiency anemia should be carefully monitorized in patients who receive long-term 288 
PPI treatment. Although future clinical study is needed, our study would caution 289 
healthcare providers to consider PPIs’ potential effects on body iron dysmetabolism.  290 
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Figure legends 356 
Fig. 1. (A) Effect of proton pump inhibitors and a histamine H2-receptor antagonist on 357 
hepcidin mRNA expression in HepG2 cells. Cells were treated with 200 µM 358 
omeprazole (OME), 50 µM lansoprazole, 100 µM pantoprazole, 12.5 µM rabeprazole, 359 
200 µM famotidine, or vehicle. Values are expressed as the mean ± SD. *P < 0.05, **P 360 
< 0.01; n = 5–10 in each group. (B) Concentration of hepcidin, secreted by HepG2 361 
cells, in the culture media. Cells were treated with either 200 µM OME or vehicle. 362 
Values are expressed as the mean ± SD. *P < 0.05 (vs. vehicle treatment); n = 3 in each 363 
group. (C) OME action on AhR translocation from the cytoplasm to the nucleus of 364 
HepG2 cells. Cells were treated with either 200 µM OME or vehicle. Values are 365 
expressed as the mean ± SD. *P < 0.05 (vs. vehicle treatment); n = 3 in each group. (D) 366 
Treatment with AhR siRNA inhibits OME-induced hepcidin upregulation in HepG2 367 
cells. Forty-eight hours after siRNA transfection, cells were treated with either 200 µM 368 
OME or vehicle. Values are expressed as the mean ± SD. **P < 0.01; n = 6–9 in each 369 




































































HepG2 cells. Cells were treated with either 200 µM OME or vehicle 1 hour after 10 371 
µM CH-223191 pretreatment. Values are expressed as the mean ± SD. **P < 0.01; n = 372 
5–10 in each group.  373 
Fig. 2. (A) Hepcidin mRNA expression in the liver of mice treated for 1 and 2 weeks 374 
with vehicle or OME. Values are expressed as the mean ± SD. **P < 0.01 (vs. vehicle 375 
treatment); n = 9–13 in each group. (B) Plasma hepcidin concentration. Values are 376 
expressed as the mean ± SD. *P < 0.05 (vs. vehicle treatment); n = 3–6 in each group. 377 
Effects of 1 and 2 weeks of treatment with vehicle or OME on the expression of FPN 378 
and tubulin in murine (C) duodenum and (D) spleen. Upper panels: Representative 379 
immunoblots. Lower panels: Semi-quantitative densitometric analyses of FPN protein 380 
levels normalized to tubulin. Values are expressed as the mean ± SD. *P < 0.05; n = 381 
6–16 in each group.  382 
Fig. 3. Effects of 1 week of treatment with vehicle or OME on protein expression in 383 
murine duodenum and spleen. Upper panels: Representative immunoblots for tubulin, 384 
(A) duodenal DMT1, (B) splenic DMT1, and (C) splenic TfR1. Lower panels: 385 
Semi-quantitative densitometric analyses of DMT1 and TfR1 protein levels normalized 386 
to tubulin. Values are expressed as means ± SD. n = 7–9 in each group. 387 
Fig. 4. (A, B) Effects of 1 week of treatment with vehicle or OME on protein 388 
expression in murine liver. Upper panels: Representative immunoblots for tubulin, (A) 389 




































































and FTL protein levels normalized to tubulin. Values are expressed as the mean ± SD. 391 
*P < 0.05; n = 4–6 in each group. (C, D) Effects of 1 week of treatment with vehicle or 392 
OME on protein expression in murine spleen. Upper panels: Representative 393 
immunoblots for tubulin, (C) FTH, and (D) FTL. Lower panels: Semi-quantitative 394 
densitometric analyses of FTH and FTL protein levels normalized to tubulin. Values 395 
are expressed as the mean ± SD.n = 4–9 in each group. 396 
Table 1. Number of reported cases and reporting odds ratio of iron deficiency anemia in patients who took proton pump inhibitors and an H2 blocker 
in FAERS analysis 
Drug name Iron deficiency anemia without drug Iron deficiency anemia with drug Reporting odds ratio (95% CI) 
Omeprazole 3275/6856188 254/136695 3.90 (3.43–4.43) 
Lansoprazole 3372/6925076 157/64277 5.02 (4.27–5.89) 
Rabeprazole 3457/6972908 72/19975 7.29 (5.77–9.21) 
Pantoprazole 3309/6892944 220/96409 4.75 (4.15–5.45) 














Data are means ± SD; n = 4-10, respectively. *P < 0.05, **P < 0.01 vs. vehicle mice at the same week. 
RBC, red blood cell; Hb, hemoglobin; Ht, hematocrit 
  1 wk  2 wk 
  Vehicle OME  Vehicle OME 
Body weight (g)  23.2 ± 0.2 22.9 ± 0.8  23.9 ± 0.9 23.5 ± 0.5 
Liver iron (µg/g protein) 125.2 ± 32.0 117.9 ± 20.7  107.2 ± 44.5 120.1 ± 47.4 
Plasma iron (µg/dL) 114.6 ± 21.1 80.8 ± 31.7*  115.7 ± 31.4 78.6 ± 15.3* 
RBC (× 104/µl) 821 ± 31 773 ± 27  867 ± 51 777 ± 18* 
Hb (g/dL) 12.0 ± 0.2 11.1 ± 0.3**  12.8 ± 0.7 11.5 ± 0.4* 














Figure 1 Hamano et al.  
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Figure 4 Hamano et al.  
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